EpiAxis Therapeutics
Overview
EpiAxis is a leading drug development company that aims to make cancer a chronic disease rather than a fatal one, by using epigenetic science to create a completely different approach to cancer treatment. Our therapies work differently to existing - and often toxic - treatments by uniquely reprograming (re-train) the cancer cells back towards normal cells. This should have the benefit of maintaining and extending cancer remission, with low side effects (compared to chemotherapy).
Key Points
- Unlike traditional cancer therapies, epigenetic therapies will be taken long term (years) with strong revenue potential
- High return on investment potential - there is strong interest in epigenetics from large pharma, with many epigenetic companies already acquired
- Multiple different cancers can be treated, meaning there is a multi-billion market opportunity
- We have already established human proof of concept in an initial breast cancer clinical trial, which means decreased the development risk
- Multiple short-mid-term value drivers, with IPO 18-24 months away
- Our products have robust intellectual protection (granted patents) across the LSD1 field
- Low operational overheads from a virtual operational model will drive your investment further
Articles
Problem and Solution
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque.
Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.
Proin neque lacus, semper vel ex at, eleifend rhoncus est.
Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a. Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.
Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl risus, vestibulum ut velit at, dapibus sagittis arcu. Nullam sed dolor suscipit, efficitur enim quis, vestibulum sapien. Nunc convallis mauris nec
Open an account to get
access to more details
Market Opportunity
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque. Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus te
Open an account to get
access to more details
Competitive Advantage
Cras eleifend purus vitae mattis imperdiet.
Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.
Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.
Fusce scelerisque massa sit amet turpis rutrum semper.
Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.
Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus eu, ornare posuere nisl. Duis venenatis accumsan eni
Open an account to get
access to more details
Highlights & Milestones
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque.
Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.
Proin neque lacus, semper vel ex at, eleifend rhoncus est.
Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a.
Open an account to get
access to more details